Literature DB >> 20682665

Impaired health-related quality of life in patients treated for Wegener's granulomatosis.

Mikkel Faurschou1, Lene Sigaard, Jakob Bue Bjorner, Bo Baslund.   

Abstract

OBJECTIVE: To investigate whether patients with Wegener's granulomatosis (WG) experience reduced health-related quality of life (HRQOL) after accomplishment of remission, and to study the influence of WG-associated organ damage on HRQOL.
METHODS: Sixty-eight patients with inactive WG and 680 randomly selected, age- and sex-matched controls of the Danish background population completed the Medical Outcomes Study Short-Form 36 (SF-36) survey for evaluation of HRQOL. Irreversible organ damage attributable to WG and/or its treatment was assessed using the Vasculitis Damage Index (VDI).
RESULTS: The median disease duration was 7.5 (range 1-26) years in the WG group, and the median total VDI score was 2.0 (range 0-7). Compared to controls, WG patients reported impaired HRQOL reflected by significantly lower SF-36 physical component summary scores (PCS) and mental component summary scores (MCS) (p < 0.001) and by significantly lower scores in 7 out of 8 SF-36 subscales (p ≤ 0.001). In the WG group, no statistically significant correlations were found between the different SF-36 scores and the total VDI score, number of organ systems affected by damage, disease duration, or number of WG relapses. Patients with organ failure or other major forms of damage did not report significantly lower HRQOL than less severely affected patients.
CONCLUSION: WG patients experience significantly reduced HRQOL even in phases with no apparent vasculitis disease activity. Our data indicate that the level of HRQOL does not correlate well with the extent of vasculitis-associated organ damage in WG.

Entities:  

Mesh:

Year:  2010        PMID: 20682665     DOI: 10.3899/jrheum.100167

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

2.  Quality of life of patients treated for giant cell arteritis: a case-control study.

Authors:  Stéphanie Jobard; Julie Magnant; Hélène Blasco; Nicole Ferreira-Maldent; Isabelle Griffoul; Elisabeth Diot; François Maillot
Journal:  Clin Rheumatol       Date:  2017-04-12       Impact factor: 2.980

Review 3.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

4.  The impact of vasculitis on patients' social participation and friendships.

Authors:  Delesha M Carpenter; Amy E Meador; Emily A Elstad; Susan L Hogan; Robert F DeVellis
Journal:  Clin Exp Rheumatol       Date:  2012-05-10       Impact factor: 4.473

5.  Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada.

Authors:  Natalie McCormick; Kathryn Reimer; Ali Famouri; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

6.  Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Arno C Hessels; Johannes H van der Hoeven; Jan Stephan F Sanders; Elisabeth Brouwer; Abraham Rutgers; Coen A Stegeman
Journal:  PLoS One       Date:  2019-02-04       Impact factor: 3.240

7.  Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI).

Authors:  Matteo Piga; Alberto Floris; Gerard Espinosa; Luísa Serpa Pinto; Nikolaos Kougkas; Andrea Lo Monaco; Giuseppe Lopalco; Ida Orlando; Vittorio Pirani; Ernestina Santos; George Bertsias; Luca Cantarini; Alberto Cauli; Ricard Cervera; João Correia; Marcello Govoni; Florenzo Iannone; Piergiorgio Neri; Ana Martins Silva; Carlos Vasconcelos; Monica Muntoni; Alessandro Mathieu
Journal:  RMD Open       Date:  2020-07

8.  The impact of current health-related quality of life on future health outlook in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  Barbara Sokołowska; Wojciech Szczeklik; Olga Piłat; Michał Wodkowski; Justyna Pieczątka; Jolanta Gąsior; Katarzyna Szczeklik; Anna Włudarczyk; Karolina Pacułt; Jacek Musiał
Journal:  Clin Rheumatol       Date:  2013-01-18       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.